Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced that the Company will present at the following upcoming investor conferences.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences:
- 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 10:40 am ET
- Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:00 am ET
- H.C. Wainwright 23rd Annual Global Investment Conference available on demand on Monday, September 13 at 7:00 am ET
- Baird’s 2021 Global Healthcare Conference on Wednesday, September 15 at 12:15 pm ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22 at 4:35 pm ET
- 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29 at 10:40 am ET
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
